Why the study?
Does recombinant modified angiopoietin-1 restore vascular architecture and rescue retinal edema and hemorrhage in murine neonates lacking mural cells?
Population
Murine neonates injected with an antagonistic mAb against PDGFR-beta to block mural cell recruitment to…
Design
Preclinical
Authors
Loading...
Hypothesis-generating for angiopoietin-1 in mural cell-deficient retinopathy; leaves open translation to human disease.
Does recombinant modified angiopoietin-1 restore vascular architecture and rescue retinal edema and hemorrhage in murine neonates lacking mural cells?
Recombinant angiopoietin-1 can restore vascular architecture and prevent leakage in the absence of mural cells, suggesting potential therapeutic utility for diseases with mural cell dropout like diabetic retinopathy.
Uemura et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: